ArticlePloS one2026
The PD-1 and CD28 molecules on T cells in peripheral blood are associated with the prognosis of patients with advanced breast cancer receiving paclitaxel chemotherapy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundT cells are the primary cell subset involved in antitumor immunity. Their functions depend largely on the repertoire of surface receptors. This study investigates the association between the expression of CD28 and PD-1 molecules on peripheral blood T cells and prognosis in advanced breast cancer (BC) patients undergoing paclitaxel chemotherapy, along with their roles in anti-tumor immunity.
methodsPeripheral blood from 61 patients with advanced BC was analyzed by flow cytometry for immunophenotype before treatment. We investigated the effects of PD-1 and CD28 on anti-tumor responses of lymphocytes in two breast cancer cell lines in vitro.
resultsPatients with high CD28 and low PD-1 on T cells were more sensitive to chemotherapy. PD-1 blockade enhanced the cytotoxicity of peripheral blood mononuclear cells (PBMCs) against tumor cells with high expression of PD-L1, an effect dependent on CD28 expression on T cells. CD28 expression is associated with immune cell infiltration in BC tumor microenvironment, particularly CD8+ T effector memory (Tem) cells. The proportion of CD8+ Tem cells increased after treatment with anti-PD-1 antibodies in vitro. Clinical results show that most patients who do not respond to chemotherapy have high expression of CD3+PD-1+ and low expression of CD8+CD28+. Combining the two markers distinguished patients with progressive disease more accurately. Additionally, patients with low CD3+PD-1+ expression and high CD8+CD28+ expression had longer progression-free survival (PFS).
conclusionThe expression of CD28 and PD-1 on T cells can serve as potential biomarkers for assessing tumor progression, chemotherapy response and prognosis in advanced BC. BC patients with low PD-1 expression or PD-1 blockade exhibit increased induction of memory T cells during the anti-tumor immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.